Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma

BACKGROUND: Interferon (IFN) alpha is one of the central agents in immunotherapy for renal cell carcinoma (RCC). It acts by binding to the IFN-alpha receptor (IFNAR). We previously reported that increased tumor expression of IFNAR2 mRNA was associated with the metastatic potential and progression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuya, Nobutaka, Kamai, Takao, Shirataki, Hiromichi, Yanai, Yoshiaki, Fukuda, Takehiko, Mizuno, Tomoya, Nakamura, Fumihiko, Kambara, Tsunehito, Nakanishi, Kimihiro, Abe, Hideyuki, Yoshida, Ken-Ichiro
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098978/
https://www.ncbi.nlm.nih.gov/pubmed/21350947
http://dx.doi.org/10.1007/s00262-011-0989-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098978/
https://www.ncbi.nlm.nih.gov/pubmed/21350947
http://dx.doi.org/10.1007/s00262-011-0989-3

Ejemplares similares